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Background: Prostaglandins are important mediators of uterine contractility and cervical ripening during labour.
Cyclooxygenase-2 (COX-2), also known as prostaglandin-endoperoxide synthase 2, is a rate limiting enzyme involved
in the conversion of arachidonic acid into prostaglandins at parturition. In this paper, the pathways underlying
agonist-induced cyclooxygenase-2 expression in human myometrial cells were studied.
Results: Myometrial cells were stimulated with different agonists: oxytocin (OXT), epidermal growth factor (EGF),
interleukin-1β (IL1β), and phorbol-12-myristate-13-acetate (PMA) alone and in the presence of specific signalling
pathway inhibitors. The nuclear factor kappa-light-chain-enhancer of activated B cells (NFKB) pathway was inhibited
by means of the IKK-2 inhibitor TPCA-1. Signalling through extracellular signal-regulated kinases (ERK) was inhibited
using the MEK1/2 inhibitor PD-184352. Bisindolylmaleimide-I was used to inhibit protein kinase C (PKC) signalling.
COX-2 expression and ERK phosphorylation were measured using immunoblotting.
OXT induced COX-2 expression by activating PKC and ERK. EGF increased COX-2 expression via stimulation of PKC,
ERK and NFKB. As expected, the pro-inflammatory cytokine IL1β induced COX-2 expression by activating PKC- and
NFKB-dependent pathways. Stimulation of PKC directly with PMA provoked strong COX-2 expression.
Conclusions: PKC plays a central role in OXT and EGF induced COX-2 expression in human myometrial cells. However,
other pathways, notably ERK and NFKB are also involved to an extent which depends on the type of agonist used.
Keywords: Prostaglandin synthase, Uterus, Regulation, Intracellular pathways, ParturitionBackground
Preterm birth is defined as birth occurring prior to
37 weeks of gestation. It affects 5-9% of all pregnancies
and is associated with more than 50% of long-term
morbidity and 75% of neonatal mortality [1,2]. Preterm
birth is a worldwide problem affecting developed and
developing countries. 15 million babies are born before
37 weeks gestation every year, with one million babies
dying from complications [3]. Approximately 7 million
children under 12 are affected by sequelae of prematurity,
ranging from mild to severe depending on their gestational
age at delivery. For example, infants born before 34 weeks
gestation have a 40 times higher frequency of cerebral palsy* Correspondence: a.lopezbernal@bristol.ac.uk
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unless otherwise stated.than infants born at term, and the incidence is 90 times
higher in infants born before 28 weeks [4,5].
Preterm birth can occur spontaneously (idiopathic) or
can be medically induced (iatrogenic) for maternal or
fetal indications, such as preeclampsia or intrauterine
growth restriction [6]. The underlying mechanisms result-
ing in spontaneous preterm labour have not been fully
elucidated; it is thought that it is either caused by a patho-
logical insult or by an early activation of the mechanism
occurring during normal labour at term [1,7].
Inflammation may play an important role in both term
and preterm parturition. During labour there is increased
synthesis of prostaglandins (PGs) within the uterus via the
induction of prostaglandin-endoperoxide synthase (PTGS),
also known as cyclooxygenase (COX) [8]. COX is a rate
limiting enzyme that is responsible for the conversion of
arachidonic acid to prostaglandin endoperoxides, which are
further converted into different prostaglandins (PGs) by celll Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and contraction of the myometrium, PGs also stimulate
cervical ripening. This remodelling process involves soft-
ening and dilatation of the cervical channel facilitating
fetal delivery [12].
There are two isoforms of COX, namely COX-1 and
COX-2 (PTGS1, PTGS2). COX-1 is a protein that is
constitutively expressed in almost all tissues whereas
the expression of COX-2 is highly regulated [11]. Ex-
pression of COX-2 in the uterus can be rapidly induced
by pro-inflammatory cytokines (e.g. interleukin (IL)1β),
growth factors (e.g. epidermal growth factor (EGF)), phor-
bol esters (e.g. phorbol-12-myristate-13-acetate (PMA))
and by the potent uterotonic hormone oxytocin (OXT)
[9,13-16].
OXT is a nanopeptide produced by the hypothalamus
and released from the posterior pituitary nerve terminals
into the circulation in a pulsatile manner [17]. As labour
progresses the frequency of OXT release increases
[18,19]. In the myometrium, OXT binds to a specific G
protein-coupled receptor (GPCR) linked through Gαq/11
to phospholipase Cβ (PLCβ). Activation of PLCβ results in
the production of inositol 1, 4, 5-trisphosphate (IP3) and
diacylglycerol (DAG) [17,20]. IP3 releases Ca
2+ from
intracellular stores. In addition, OXT receptor (OXTR)
activation increases intracellular Ca2+ by stimulating extra-
cellular Ca2+ entry through cell membrane channels in
human myometrial cells [21]. Increases in intracellular
Ca2+ are essential to stimulate myometrial contractility;
moreover OXTR mediated Ca2+ entry stimulates nu-
clear transcription in human myometrial cells through
calcineurin/NFAT (nuclear factor of activated T cells)
signalling [22].
DAG is a lipid second messenger that is capable of
activating conventional and novel protein kinase C (PKC)
isoforms [23]. The phorbol ester, PMA activates PKC
by mimicking the function of DAG. Activation of con-
ventional PKC isoforms can however only happen in
the presence of both DAG and Ca2+ [24]. PKC can
stimulate different pathways e.g. mitogen-activated protein
kinases (MAPK) such as extracellular signal-regulated kin-
ase (ERK), and nuclear factor kappa-light-chain-enhancer
of activated B cells (NFKB) both shown to be involved
in labour [15,25]. Activation of these pathways can
happen under control of PKC or independently of this
kinase [26,27]. It has been reported that OXT induces
myometrial COX-2 expression and stimulates PG synthe-
sis through activation of ERK and that this process is en-
tirely PKC independent [15,28]. On the other hand, PKC
activity has been demonstrated to be important during
OXT-mediated myometrial contractions [29]. Recently, we
have shown that OXT induces COX-2 mRNA expression
in myometrial cells through activation of the calcineurin/
NFAT pathway [22].The growth factor EGF accumulates in the amniotic
fluid throughout pregnancy and is present in maternal
and fetal blood [30,31]. EGF exerts its function by binding
to the EGF receptor (EGFR, the first described member of
the proto-oncogene ErbB tyrosine kinase family). Binding
of EGF to the EGFR stimulates its tyrosine kinase activity
via an allosteric mechanism involving the formation of
asymmetric intracellular kinase domains. The phosphory-
lated EGFR recruits adaptor proteins and activates several
major signalling cascades including MAPK, PLCγ, PKC,
PI3 kinase-AKT and NFKB [32]. EGF stimulates COX-2
expression in human amnion cells and prostaglandin pro-
duction in cultured myometrial cells [33,34]. The mechan-
ism of action of EGF has been investigated in many cell
types, including amnion cells, and the consensus is that
EGFR operates primarily through ERK activation to
stimulate COX-2 gene expression, with little involvement
of PKC [14,35]; however, the mediators involved in EGFR
signalling in myometrial cells have not been described.
The pro-inflammatory cytokine IL1β is a potent stimu-
lator of COX-2 expression in human myometrial cells
[36]. During pregnancy the concentration of this cytokine
increases in the amniotic fluid [37]. It has been reported
that IL1β induces myometrial COX-2 expression via acti-
vating PKC and NFKB [27,36].
The aim of this study was to investigate the pathways
mediating OXTR and EGFR-induced COX-2 expression
in human myometrial cells, and in particular the role of
the ERK and PKC pathways. We have also compared
the effect of OXT and EGF with the pro-inflammatory
cytokine IL1β under the same conditions. The results
demonstrate that OXT, EGF and IL1β induced COX-2 ex-
pression in myometrial cells is mainly PKC dependent.
Our findings contribute towards a better understanding of
the mechanisms leading to spontaneous term and preterm
labour.
Results
Oxytocin stimulates myometrial COX-2 expression via
signalling through PKC and ERK
Myometrial cells were stimulated with 1 μM OXT for
6 hours in the absence and in the presence of different
inhibitors. Signalling through NFKB was inhibited by
means of an IKK-2 inhibitor, TPCA-1 (2 μM). The ERK
pathway was inhibited using the MEK1/2 inhibitor,
PD-184352 (2 μM). Bisindolylmaleimide-I (BIS1; 5 μM)
was used to inhibit PKC signalling. After stimulating the
cells with OXT they were lysed and subjected to immuno-
blotting with a COX-2 antibody. Control wells were incu-
bated with inhibitors in the absence of OXT. None of
the inhibitors alone had any effect on COX-2 expression
(data not shown). As shown in Figure 1, stimulation of
myometrial cells with OXT resulted in a fourfold in-
crease (P < 0.001) in COX-2 expression. This increase
Figure 1 Mechanism of OXT induced COX-2 expression in human myometrial cells. Cells were stimulated with 1 μM OXT for 6 hours in the
absence and in the presence of different inhibitors. The NFKB pathway was inhibited using TPCA-1 (2 μM). PD-184352 (2 μM) was used to test
the ERK pathway. Signalling through PKC was inhibited by means of Bisindolylmaleimide I (BIS1; 5 μM). (A) Cell lysates were subjected to
immunoblotting for COX-2. Blots were stripped and re-probed for GAPDH. (B) COX-2 expression was normalised to GAPDH expression and given
as a percentage of the OXT treated value. Data points represent mean ± SEM, n = 5. Statistical significance was determined using one way ANOVA
and Dunnett’s post hoc test. ***P < 0.001.
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(P <0.001) and BIS1 (P <0.001). When both inhibitors
were used in combination there was a further decrease
in OXT induced COX-2 expression to control levels,
but this decrease did not reach statistical significance
(Figure 1).
To demonstrate that the ERK pathway was active in
response to OXT, we measured ERK phosphorylation
directly. Cells were stimulated with 1 μM OXT for dif-
ferent time points (2-, 5-, 10-, and 20-minutes) with and
without pre-treatment with 5 μM BIS1. Lysates were
used for immunoblotting with a pERK antibody. Blots
were stripped and re-probed for ERK, to which the phos-
phorylation of ERK was normalised. As shown in Figure 2,
ERK phosphorylation increased with OXT stimulation
with a maximal response at 5 minutes (P < 0.001). TheFigure 2 OXT stimulates ERK phosphorylation in primary human myo
different time points (2-, 5-, 10-, and 20-minutes) in the absence or presenc
using a phospho-ERK antibody. Blots were stripped and re-probed for ERK.
expression and non-treated values. Data points represent mean ± SEM, n =
Bonferroni post hoc test. **P < 0.01 and ***P < 0.001.response to OXT was transient and at 20 minutes pERK
levels were below control levels, possibly due to OXT
receptor desensitization and phosphatase induction.
The PKC inhibitor BIS1 provoked a significant decrease in
ERK phosphorylation (P < 0.001).
EGF stimulates COX-2 expression via signalling through
ERK and PKC
To investigate EGF induced COX-2 expression, cells were
stimulated with 25 ng/ml EGF for 6 hours in the absence
and in the presence of different inhibitors (2 μM TPCA-1,
2 μM PD-184352 and 5 μM BIS1). As shown in Figure 3,
EGF provoked a significant increase in COX-2 expression
(3.9 fold; P < 0.001). This increase was significantly
inhibited in the presence of TPCA-1 (P < 0.01), PD-
184352 (P < 0.001) and BIS1 (P < 0.001). The inhibitorymetrial cells. Myometrial cells were stimulated with 1 μM OXT for
e of BIS1 (5 μM). (A) Cell lysates were subjected to immunoblotting
(B) Fold change in ERK phosphorylation normalised to total ERK
3. Statistical significance was determined using two way ANOVA and
Figure 3 Mechanisms of EGF induced COX-2 expression in primary human myometrial cells. Cells were stimulated with 25 ng/ml EGF
for 6 hours alone or in the presence of different inhibitors (2 μM TPCA-1, 2 μM PD-184352 and 5 μM BIS1). (A) Cell lysates were subjected to
immunoblotting using a COX-2 antibody. Blots were stripped and re-probed for GAPDH. (B) COX-2 expression normalised to GAPDH expression
and given as a percentage of the EGF treated value. Data points represent mean ± SEM, n = 3. Statistical significance was determined by means of
one way ANOVA and Dunnett’s post hoc test. ** P < 0.01 and ***P < 0.001.
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expression down to control levels. TPCA-1 was the
weakest inhibitor, with BIS1 having an intermediate
effect. The combination of PD-184352 and BIS1 had
the same effect as PD-184352 alone (Figure 3).
To study the effect of EGF on ERK activation, cells were
stimulated with 25 ng/ml EGF in the absence or presence
of 5 μM BIS1 for different time points (2-,5-,10-, and 20-
minutes). As depicted in Figure 4, stimulation of myome-
trial cells with EGF resulted in a marked increase in ERK
phosphorylation with a maximal response after a stimula-
tion of 20 min. The PKC inhibitor BIS1 was unable to
block this effect (Figure 4) demonstrating its specificity to-
wards PKC in our system.Figure 4 EGF induces ERK phosphorylation in human myometrial cell
(2-, 5-, 10-, and 20-min) in the absence or presence of 5 μM BIS1. (A) ERK p
phospho-ERK antibody. Blots were stripped and re-probed for ERK. (B) Fold
and non-treated values. Data points represent mean ± SEM, n = 3. Statistica
post hoc test. * P < 0.05, **P < 0.01.IL1β increases COX-2 expression via activating NFKB
and PKC
The pro-inflammatory cytokine IL1β is a potent activator
of COX-2 expression. Cells were stimulated for 6 hours
with 5 ng/ml IL1β alone or in combination with different
inhibitors (TPCA-1 (2 μM), PD-184352 (2 μM) and BIS1
(5 μM)). Cells were lysed and subjected to immunoblot-
ting for COX-2. As expected, IL1β stimulated COX-2
expression in myometrial cells very strongly (8.5 fold;
P < 0.001). This effect was significantly inhibited by
TPCA-1 (P < 0.01) and BIS1 (P < 0.001) indicating that
both NFKB and PKC are involved in IL1β induced
COX-2 expression (Figure 5). The ERK pathway on the
other hand did not seem to contribute to this effect.s. Cells were stimulated with 25 ng/ml EGF for different time points
hosphorylation was studied by means of immunoblotting using a
change in ERK phosphorylation normalised to total ERK expression
l significance was determined using two way ANOVA and Bonferroni
Figure 5 Mechanisms of IL1β induced COX-2 expression in myometrial cells. Cells were stimulated with 5 ng/ml IL1β for 6 hours alone or
in the presence of different inhibitors (2 μM TPCA-1, 2 μM PD-184352 and 5 μM BIS1). (A) Lysed cells were subjected to immunoblotting using a
COX-2 antibody. Blots were stripped and re-probed for GAPDH. (B) COX-2 expression was normalised to GAPDH expression and given as a
percentage of the IL1β treated value. Data points represent mean ± SEM, n = 5. Statistical significance was determined using one way ANOVA and
Dunnett’s post hoc test. **P < 0.01 and ***P < 0.001.
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ling plays an important role in agonist-induced COX-2
expression. PMA activates PKC directly and is a potent
activator of COX-2 expression in myometrial cells [27]. We
used PMA as a tool to further investigate the involvement
of PKC in agonist-induced COX-2 expression in our
system.
PMA induced COX-2 expression: involvement of ERK
Myometrial cells were stimulated with 2 μM PMA for
6 hours alone and in combination with different in-
hibitors (2 μM TPCA-1, 2 μM PD-184352 and 5 μM
BIS1). Effects on COX-2 expression were studied by
means of immunoblotting using a COX-2 antibody.
As shown in Figure 6, PMA was a potent stimulus for
COX-2 expression in human myometrial cells (10.8
fold; P < 0.001). However, the presence of the MEK in-
hibitor, PD-184352, significantly (P < 0.001) decreased
COX-2 expression. The PKC inhibitor, BIS1, com-
pletely abolished the effect of PMA on COX-2 expression
(P < 0.001).
To test for ERK phosphorylation, myometrial cells
were stimulated with 2 μM PMA for different time
points (2-, 5-, 10-, and 20-minutes). Stimulation of
myometrial cells with PMA resulted in an increase in
ERK phosphorylation with a maximal response after
10 min of stimulation (P < 0.001; Figure 7). Two clear
phosphoERK1 and phosphoERK2 bands were detected
by the pERK antibody, with preferential phosphoryl-
ation of ERK2. The PKC inhibitor BIS1 inhibited this
effect (P < 0.001) and also decreased basal levels of
ERK phosphorylation.Discussion
This study provides the first direct comparison of the
effect of OXT and EGF in human myometrial cells and
demonstrated that both agonists require PKC activity to
stimulate COX-2 expression. Given the importance of
COX-2 up-regulation for the onset of labour and the
involvement of GPCR and tyrosine kinase receptors in
the control of uterine activation [7], we decided to
investigate the mechanism by which OXT and EGF
increase COX-2 expression in myometrial cells, in par-
ticular the role of PKC which has been questioned in
previous studies [15].
OXT plays an important role during parturition by
stimulating myometrial contractility and promoting the
expression of labour-associated genes [22]. Moreover
OXT has paracrine interactions with IL1β in human
amnion to increase COX-2 expression and stimulate PG
production [38]. Increased PG release leads to further
paracrine and autocrine effects facilitating uterine activa-
tion, for instance PGF2α stimulates OXTR and COX-2
expression in human myometrial cells [39]. Molnar et al.
[15] reported that OXT induces COX-2 expression in
myometrial cells by activating the ERK pathway and sug-
gested that this is entirely PKC independent. We have
confirmed that OXT increases myometrial COX-2 expres-
sion via ERK stimulation. However, in contrast to Molnar
et al. our study reveals that the stimulatory effect of OXT
on COX-2 expression is dependent on PKC activation as
shown by the blocking effect of BIS1, a PKC inhibitor.
BIS1 had an inhibitory effect on basal levels of ERK phos-
phorylation at the concentration used, however this is
likely to be due to inhibition of constitutive PKC activity
Figure 6 Mechanisms of PMA induced COX-2 expression in myometrial cells. Cells were stimulated for 6 hours with the PKC activator, PMA
(2 μM) alone or in the presence of different inhibitors (TPCA-1 (2 μM), PD-184352 (2 μM) and BIS1 (5 μM)). (A) After lysis the cells were subjected
to immunoblotting using a COX-2 antibody. Blots were stripped and re-probed for GAPDH. (B) COX-2 expression normalised to GAPDH expression
and given as a percentage of the PMA treated value. Data points represent mean ± SEM, n = 5. Statistical significance was determined using one way
ANOVA and Dunnett’s post hoc test. ***P < 0.001.
Wouters et al. BMC Research Notes 2014, 7:357 Page 6 of 10
http://www.biomedcentral.com/1756-0500/7/357in myometrial cells. BIS1 had no effect on EGF-stimulated
ERK phosphorylation; hence its inhibitory effect on OXT-
induced COX-2 expression is likely to be due to its PKC
blocking effect and not due to non-specific inhibition of
ERK. It is possible that during pregnancy the myometrium
becomes more responsive to PKC signalling [40] and this
is reflected in our results.
MEK1/2 and PKC inhibitors were capable of blocking
OXT-induced COX-2 expression almost completely when
given separately. When they were used in combination, a
small additional inhibitory effect was visible. This indicates
that both ERK and PKC signalling mediate OXT stimu-
lated COX-2 expression. Moreover, OXT increased ERK
phosphorylation and this was significantly inhibited in the
presence of BIS1.
The concentration of EGF increases in the amniotic
fluid during pregnancy [31]. EGF exerts its function byFigure 7 PMA induces ERK phosphorylation in myometrial cells. Myom
(2-, 5-, 10-, and 20-minutes) in the presence of 5 μM BIS1. (A) Cell lysates w
were stripped and reprobed for ERK. (B) Fold change in ERK phosphorylatio
n = 3. Statistical significance was determined using two way ANOVA and Bbinding to EGF-receptor dimers and promoting tyrosine
phosphorylation of other proteins. It has been shown
that EGF activates PKC in human myometrial cells and
that it can induce PG production in these cells [33,41].
In human amnion EGF induces COX-2 expression [34,35].
The involvement of EGF in COX-2 expression in human
myometrial cells has not been studied before. Our results
show that EGF stimulates COX-2 expression in myometrial
cells and that this is dependent on the activation of PKC,
ERK and NFKB. The inhibitory effect of PD-184352 was
the strongest, followed by that of BIS1, with TPCA-1 having
only a moderate effect. The addition of BIS1 to PD-184352
produced an inhibitory effect similar to that with PD-
184352 alone. This suggests that the ERK pathway is the
most important, but there is also a strong PKC compo-
nent. There is interaction between the two pathways in
EGFR and OXT receptor mediated COX-stimulation inetrial cells were stimulated with 2 μM PMA for different time points
ere subjected to immunoblotting using a phospho-ERK antibody. Gels
n relative to non-treated values. Data points represent mean ± SEM,
onferroni post hoc test. **P < 0.01 and ***P < 0.001.
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myometrial cells EGF stimulated ERK phosphorylation
largely in a PKC independent manner. The role of EGF in
stimulating COX-2 expression is worth investigating fur-
ther, in particular given the capacity of OXT receptors to
trans-activate EGFR tyrosine kinase leading to ERK1/2
activation in myometrial cells [43].
IL1β is a potent stimulator of COX-2 expression and
exposure of myometrial cells to this agonist resulted in a
9-fold increase in COX-2 expression. It has been shown
that IL1β induces COX-2 expression in human myome-
trial cells by activating the PKC and NFKB pathways
[27,36] and we have confirmed this here. Moreover, we
have shown that compared to OXT, IL1β is relatively
more dependent on the NFKB pathway to stimulate
COX-2 expression; however, both agonist rely mainly on
PKC signalling.
A potential limitation of this study is that we did not
have a positive control for the inhibitor in each individual
experiment; however controls are presented throughout
the work: for the IKK-2 inhibitor TPCA-1 positive control
in Figure 5 and negative control in Figure 6; for the
MEK1/2 inhibitor PD-184352 positive control in Figure 3
and negative control in Figure 5; for the PKC inhibitor
BIS1 positive control in Figure 6 and negative control in
Figure 4. This confirms the consistency of the data.
TPCA-1 is a selective IKK-2 inhibitor that has been
extensively characterised in human intrauterine tissues;
it inhibits p65 translocation and reduces the expression
of genes associated with inflammatory signalling via the
NFKB pathway [44]. However IKK-2 also phosphorylates
other targets in addition to those involved in NFKB activa-
tion, such as beta-catenin and BCL10 which play import-
ant roles in cell division and apoptosis. Silva et al. (2010)
[44] reported no side effects of TPCA-1 in choriodecidual
cells and we did not observe signs of cytotoxicity in our
myometrial cell cultures at the doses of TPCA used. PD
184352 is a highly potent non-competitive inhibitor of
MEK1 and MEK2; it suppresses the activation of MEK1,
rather than blocking its activity. The selectivity of PD
184352 for MEK against a wide range of kinases is ex-
cellent [45]. BIS1 is a PKC inhibitor that shows high
selectivity for PKC α-, β1-, β2-, γ-, δ-, and ε-isozymes in
uterine tissues [46]. However, as with other bisindolyl-
maleimides, the possibility that it also inhibits protein
kinases of the RSK and GSK3 families cannot be ruled
out [45].
Overall, our results show that PKC plays a central role
in agonist-induced COX-2 expression in myometrial
cells. When PKC was stimulated directly using PMA
there was a large increase in COX-2 expression in the
cells. In the presence of PD-184352 a significant decrease
in COX-2 expression was observed. BIS1 on the other
hand completely inhibited the effect of PMA on COX-2expression, which shows that PKC can stimulate COX-2
expression independently of ERK. Little or no additive in-
hibitory effect was observed when the MEK1/2 and PKC
inhibitors were used in combination, indicating that the
PKC-effect is not entirely ERK mediated.
Conclusion
In conclusion, there is strong evidence for the involvement
of PKC in agonist-induced COX-2 expression in human
myometrial cells (Figure 8). This is the most important
pathway for both physiological and inflammatory agonists.
The effect of PKC appears to lie upstream of ERK but we
cannot rule out that the two kinase pathways act inde-
pendently of each other to convert receptor signalling into
COX-2 stimulation. The relative prominence of each path-
way in myometrial cells depends on the type of agonist
used. These findings contribute to our understanding of
myometrial preparation for parturition and respond to the
need to investigate myometrial specific mechanisms in
order to develop tocolytic drugs with better uterine select-
ivity. The data will inform further research not only into
the prevention of preterm labour, but also into the induc-
tion or augmentation of labour where increased expression
of COX-2 is important.
Methods
Tissue collection
This study was approved by the South West Research
Ethics Committee and specimens were collected after
obtaining informed written consent. Human myometrial
smooth muscle samples were obtained from pregnant
women at term (not in labour) undergoing caesarean
section at St Michael’s Hospital (Bristol, UK). Caesarean
section was performed following maternal request, fetal
malposition or previous section. Women with signs of
infection were excluded. Myometrial samples were taken
from the upper margin of the incision and washed in
ice-cold isotonic saline before being transported to the
laboratory.
Myometrial cell culture
Human myometrial tissue was enzymatically dispersed
into single cells in serum-free DMEM (Invitrogen, Paisley,
UK) containing collagenase type II (300 U/ml; Invitrogen),
dispase (0.3 U/ml; Invitrogen), DNase (30 U/ml; Sigma
Aldrich, Poole, UK) and elastase (0.09 U/ml; Sigma
Aldrich) at 37°C for 4.5 h with shaking. Liberated cells
were cultured in T75 flask in DMEM supplemented with
10% (v/v) fetal calf serum (FCS; Invitrogen), 100 U/ml
penicillin (Invitrogen) and 100 μg/ml streptomycin (Invi-
trogen) at 37°C and 5% CO2. Cells were seeded at 4 × 10
4
cells/well in 24-well plates (Greiner Bio-One Ltd,
Stonehouse, Gloucestershire, UK) and grown to confluence
Figure 8 Schematic diagram. Underlying signalling pathways activated by OXT, EGF and IL1β to stimulate COX-2 expression in human
myometrial cells. The relative importance of each signalling pathway is represented by its size.
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used between passages 2–10.
Agonist stimulation of myometrial cells
Cells were incubated overnight in DMEM containing 2%
(v/v) FCS, 100 U/ml penicillin and 100 μg/ml strepto-
mycin. Before treatment, the medium was changed to
Krebs solution (4.7 mM KCl, 1.25 mM MgSO4, 2.5 mM
NaH2PO4, 1.25 mM CaCl2, 130 mM NaCl, 25 mM
NaHCO3, 11.1 mM glucose, 10 mM Hepes pH 7.6 and
0.1% (w/v) bovine serum albumin (BSA)) and cells were
pre-incubated for 30 minutes with inhibitors (TPCA-1
(Sigma Aldrich), 2 μM; PD-184352 (Tocris), 2 μM;
Bisindolylmaleimide-I (BIS1; Tocris), 5 μM) followed
by the administration of agonists (OXT (Sigma Aldrich),
1 μM; EGF (Merck), 25 ng/ml; IL1β (Cell Guidance Sys-
tems, Cambridge, UK), 5 ng/ml; PMA (Sigma Aldrich),
2 μM). Cells were stimulated for 6 hours with a refresh-
ment of medium containing agonists and inhibitors every
two hours. After treatment, cells were washed with
phosphate-buffered saline (PBS), lysed in boiling sodium
dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) sample buffer (25 mM Tris pH 6.8, 2% (w/v)
SDS, 0.002% (w/v) bromophenol blue, 10% (v/v) glycerol
and 12.5 mM dithiothreitol) and used for immunoblotting
as described below.
For some experiments, cells were pre-incubated with
BIS1 for 30 minutes followed by stimulation with agonists
for different time points (2-, 5-, 10-, and 20-minutes). Be-
fore using for immunoblotting, cells were rinsed in PBSand lysed in boiling SDS-PAGE sample buffer. Cells that
were not pre-incubated with inhibitors received 0.1% (v/v)
dimethyl sulphoxide (DMSO; vehicle for BIS1) in the
presence or absence of agonist.
Immunoblotting
Samples used for immunoblotting were separated on 8%
Bis-Tris gels (357 mM Bis-Tris pH 6.75, 8% (w/v)
acrylamide, 0.27% (w/v) bis-acrylamide) in MOPS run-
ning buffer (250 mM MOPS, 250 mM Tris, 5 mM
EDTA and 0.5% (w/v) SDS). Proteins were transferred
by wet transfer to a PVDF membrane (GE Healthcare,
Buckinghamshire, UK) at 80 V for 70 minutes in trans-
fer buffer (25 mM Tris, 192 mM glycine and 10% (v/v)
methanol). Nonspecific binding was blocked by incubating
the membranes in 5% (w/v) BSA in Tris-buffered saline
containing 0.1% (v/v) Tween-20 (TBS-T) for 1 hour.
Subsequently, membranes were incubating with primary
antibodies (COX-2 (Abcam, Cambridge, UK), 1:1000;
GAPDH (Abcam), 1:5000; P44/42 MAPK (ERK1/2) (Cell
Signaling Technology, Danvers, MA, USA), 1:4000; Phos-
pho-p44/42 MAPK (Cell Signaling Technology), 1:1000)
in 5% (w/v) BSA/TBS-T overnight at 4°C. After 6
washes in TBS-T for 5 minutes, membranes were incu-
bated for 1 hour at room temperature with a horseradish
peroxidase-conjugated goat anti-rabbit antibody (1:4000;
Cell Signaling Technology) in TBS-T. Membranes were
washed in TBS-T (6 × 5 minutes) and protein bands
were detected with ECL western blot detection reagents
(GE Healthcare, Amersham, Buckinghamshire, UK) using
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veloped by means of a KODAK X-OMAT 1000 Processor
(Kodak, NY, USA). For re-probing, membranes were incu-
bated for 3 × 1 hour in stripping buffer (20 mM glycine
and 1% (w/v) SDS, pH 2) followed by incubation in pri-
mary antibody. Protein bands were quantified using
Quantity One software (Bio-Rad, Hemel Hempstead,
UK). Raw data was normalized to the value of the non-
stimulated control. COX-2 expression was normalized
to the expression of GAPDH and the level of ERK
phosphorylation was normalized to the level of total
ERK. ERKs are activated by dual phosphorylation of
conserved residues within the motif Thr-Glu-Tyr [47].
The phospho-antibody we used recognises ERK1/2 when
phosphorylated at Thr202 and Tyr204 (ERK1) or Thr185
and Tyr187 (ERK2) in the activation loop.
Statistical analysis
Statistical analysis was performed by means of GraphPad
Prism (GraphPad Software, La Jolla, CA, USA) using
one-way ANOVA followed by the Dunnett post hoc test
and two-way ANOVA with a Bonferroni post hoc test.
Values are shown as the mean ± SEM of 3 to 5 replicate
experiments using tissue from different donors. Differ-
ences were considered statistically significant at P < 0.05.
*P < 0.05, **P < 0.01 and ***P < 0.001.
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